Neuro-oncology: the growing role of chemotherapy in glioma.
Carpentier
Antoine F
AF
Department of Neurology Mazarin, Salpêtrière hospital and University Paris 5, France. antoine.carpentier@psl.ap-hop-paris.fr
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000235:genetics; D017024:Chemotherapy, Adjuvant; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm; D000077156:Gefitinib; D005909:Glioblastoma / Q000188:drug therapy; D005910:Glioma / Q000150:complications / Q000188:drug therapy* / Q000235:genetics; D006801:Humans; D015201:Meta-Analysis as Topic; D009607:Nitrosourea Compounds / Q000627:therapeutic use; D009837:Oligodendroglioma / Q000188:drug therapy; D010257:Paraneoplastic Syndromes / Q000209:etiology; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use; D018714:Radiotherapy, Adjuvant; D016032:Randomized Controlled Trials as Topic; D000077204:Temozolomide
D000970:Antineoplastic Agents; D018906:Antineoplastic Agents, Alkylating; D009607:Nitrosourea Compounds; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D003606:Dacarbazine; D000077156:Gefitinib; D000077204:Temozolomide